HIF-1α also plays a crucial role in the glycolytic reprogramming of TAMs [183, 184]; consequently, inhibition of HIF-1 and HIF-2 has been shown to suppress hepatocellular carcinoma growth and enhance the efficacy of anti-programmed death 1 (PD1) therapy [185]. This evidence concerns the gene HIF1A and hepatocellular carcinoma.